ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.
A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.
The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.
The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.
Shares of the company were down 9.3% in recent Friday trading.
Price: 0.55, Change: -0.06, Percent Change: -9.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。